Date: Thursday 11th July 2024
Time: 15:00 BST | 10:00 EDT | 07:00 PDT
Location: Online webinar
With the launch of Project Optimus, the FDA is reforming the dose optimization and dose selection paradigm in oncology drug development. The initiative addresses the issue of poorly characterized doses and schedules, which can lead to increased toxicity without additional efficacy. This transformation necessitates significant changes in how early phase trials are designed and conducted.
Under the framework of Project Optimus there are many considerations drug developers will need to consider within their early clinical trial development, including how they justify their dose range through into Phase II. This will naturally impact on time and cost requiring more strategic and robust methodologies. Ensuring regulatory compliance involves aligning trial designs with new FDA guidelines, utilizing novel methodologies to reduce trial duration and resource use, incorporating new technologies, and engaging with regulatory experts for proactive planning. Flexibility and adaptation are crucial, as traditional methodologies may need modification to comply with new standards.
Gain an introductory understanding of Project Optimus.
Learn about the impact on oncology trials and drug development.
Discover strategies to navigate the new regulatory landscape.
For more information and to register, please visit: https://info.phastar.com/webinar-navigating-project-optimus-fda
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
This webinar will discuss opportunities in applying causal inference methodology during the analysis of RCT data.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This apprenticeship role offers a unique opportunity to learn and work in a global healthcare consultancy company alongside a team of statisticians, psychometricians and programmers.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
